218 related articles for article (PubMed ID: 29110053)
21. ACR Appropriateness Criteria
; Qayyum A; Tamm EP; Kamel IR; Allen PJ; Arif-Tiwari H; Chernyak V; Gonda TA; Grajo JR; Hindman NM; Horowitz JM; Kaur H; McNamara MM; Noto RB; Srivastava PK; Lalani T
J Am Coll Radiol; 2017 Nov; 14(11S):S560-S569. PubMed ID: 29101993
[TBL] [Abstract][Full Text] [Related]
22. [Radiological evaluation of pancreatic ductal adenocarcinoma].
Akai H; Otomo K
Gan To Kagaku Ryoho; 2012 Mar; 39(3):342-6. PubMed ID: 22421758
[TBL] [Abstract][Full Text] [Related]
23. The oncogenic kinase Pim-1 is modulated by K-Ras signaling and mediates transformed growth and radioresistance in human pancreatic ductal adenocarcinoma cells.
Xu D; Allsop SA; Witherspoon SM; Snider JL; Yeh JJ; Fiordalisi JJ; White CD; Williams D; Cox AD; Baines AT
Carcinogenesis; 2011 Apr; 32(4):488-95. PubMed ID: 21262926
[TBL] [Abstract][Full Text] [Related]
24. Response assessment in pancreatic ductal adenocarcinoma: role of imaging.
Baliyan V; Kordbacheh H; Parakh A; Kambadakone A
Abdom Radiol (NY); 2018 Feb; 43(2):435-444. PubMed ID: 29243123
[TBL] [Abstract][Full Text] [Related]
25. CT Abnormalities of the Pancreas Associated With the Subsequent Diagnosis of Clinical Stage I Pancreatic Ductal Adenocarcinoma More Than 1 Year Later: A Case-Control Study.
Toshima F; Watanabe R; Inoue D; Yoneda N; Yamamoto T; Sasahira N; Sasaki T; Matsuyama M; Minehiro K; Tateishi U; Gabata T
AJR Am J Roentgenol; 2021 Dec; 217(6):1353-1364. PubMed ID: 34161128
[No Abstract] [Full Text] [Related]
26. Intravoxel incoherent motion DWI of the pancreatic adenocarcinomas: monoexponential and biexponential apparent diffusion parameters and histopathological correlations.
Ma C; Li Y; Wang L; Wang Y; Zhang Y; Wang H; Chen S; Lu J
Cancer Imaging; 2017 Apr; 17(1):12. PubMed ID: 28454564
[TBL] [Abstract][Full Text] [Related]
27. Pancreatic ductal adenocarcinoma staging.
Al-Hawary MM; Francis IR
Cancer Imaging; 2013 Sep; 13(3):360-4. PubMed ID: 24060977
[TBL] [Abstract][Full Text] [Related]
28. Pancreatic Ductal Adenocarcinoma: The Dawn of the Era of Nuclear Medicine?
Montemagno C; Cassim S; De Leiris N; Durivault J; Faraggi M; Pagès G
Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34203923
[TBL] [Abstract][Full Text] [Related]
29. Applicability of current NCCN Guidelines for pancreatic adenocarcinoma resectability: analysis and pitfalls.
Garces-Descovich A; Beker K; Jaramillo-Cardoso A; James Moser A; Mortele KJ
Abdom Radiol (NY); 2018 Feb; 43(2):314-322. PubMed ID: 29392370
[TBL] [Abstract][Full Text] [Related]
30. A treatment planning comparison of four target volume contouring guidelines for locally advanced pancreatic cancer radiotherapy.
Fokas E; Eccles C; Patel N; Chu KY; Warren S; McKenna WG; Brunner TB
Radiother Oncol; 2013 May; 107(2):200-6. PubMed ID: 23647755
[TBL] [Abstract][Full Text] [Related]
31. Hypofractionated ablative radiotherapy for locally advanced pancreatic cancer.
Crane CH
J Radiat Res; 2016 Aug; 57 Suppl 1(Suppl 1):i53-i57. PubMed ID: 27029741
[TBL] [Abstract][Full Text] [Related]
32. Role of imaging biomarkers for prognostic prediction in patients with pancreatic ductal adenocarcinoma.
Cui SJ; Tang TY; Zou XW; Su QM; Feng L; Gong XY
Clin Radiol; 2020 Jun; 75(6):478.e1-478.e11. PubMed ID: 32037002
[TBL] [Abstract][Full Text] [Related]
33. Medical oncology and pancreatic cancer: what the radiologist needs to know.
Fogelman DR; Varadhachary G
Abdom Radiol (NY); 2018 Feb; 43(2):383-392. PubMed ID: 29285600
[TBL] [Abstract][Full Text] [Related]
34. Stereotactic body radiotherapy (SBRT) in recurrent or oligometastatic pancreatic cancer : A toxicity review of simultaneous integrated protection (SIP) versus conventional SBRT.
Gkika E; Adebahr S; Kirste S; Schimek-Jasch T; Wiehle R; Claus R; Wittel U; Nestle U; Baltas D; Grosu AL; Brunner TB
Strahlenther Onkol; 2017 Jun; 193(6):433-443. PubMed ID: 28138949
[TBL] [Abstract][Full Text] [Related]
35. Association between hyperechogenic pancreas and pancreatic ductal adenocarcinoma concomitant with intraductal papillary mucinous neoplasms.
Mandai K; Uno K; Nakase K; Kawamura T; Yasuda K
J Med Ultrason (2001); 2019 Oct; 46(4):435-439. PubMed ID: 31069577
[TBL] [Abstract][Full Text] [Related]
36. Utility of CT Radiomics Features in Differentiation of Pancreatic Ductal Adenocarcinoma From Normal Pancreatic Tissue.
Chu LC; Park S; Kawamoto S; Fouladi DF; Shayesteh S; Zinreich ES; Graves JS; Horton KM; Hruban RH; Yuille AL; Kinzler KW; Vogelstein B; Fishman EK
AJR Am J Roentgenol; 2019 Aug; 213(2):349-357. PubMed ID: 31012758
[No Abstract] [Full Text] [Related]
37. Contrast enhanced 4D-CT imaging for target volume definition in pancreatic ductal adenocarcinoma.
Mancosu P; Bettinardi V; Passoni P; Gusmini S; Cappio S; Gilardi MC; Cattaneo GM; Reni M; Del Maschio A; Di Muzio N; Fazio F
Radiother Oncol; 2008 Jun; 87(3):339-42. PubMed ID: 18486253
[TBL] [Abstract][Full Text] [Related]
38. Pancreatic adenocarcinoma: variability in measurements of tumor size among computed tomography, magnetic resonance imaging, and pathologic specimens.
Ma C; Yang P; Li J; Bian Y; Wang L; Lu J
Abdom Radiol (NY); 2020 Mar; 45(3):782-788. PubMed ID: 31292672
[TBL] [Abstract][Full Text] [Related]
39. A nationwide randomized controlled trial on additional treatment for isolated local pancreatic cancer recurrence using stereotactic body radiation therapy (ARCADE).
van Goor IWJM; Daamen LA; Besselink MG; Bruynzeel AME; Busch OR; Cirkel GA; Groot Koerkamp B; Haj Mohammed N; Heerkens HD; van Laarhoven HWM; Meijer GJ; Nuyttens J; van Santvoort HC; van Tienhoven G; Verkooijen HM; Wilmink JW; Molenaar IQ; Intven MPW;
Trials; 2022 Oct; 23(1):913. PubMed ID: 36307892
[TBL] [Abstract][Full Text] [Related]
40. A Novel Approach for Image-Guided
Schug C; Gupta A; Urnauer S; Steiger K; Cheung PF; Neander C; Savvatakis K; Schmohl KA; Trajkovic-Arsic M; Schwenk N; Schwaiger M; Nelson PJ; Siveke JT; Spitzweg C
Mol Cancer Res; 2019 Jan; 17(1):310-320. PubMed ID: 30224540
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
